Comparative efficacy of Chinese-developed versus imported PD-1/PD-L1 inhibitors in first-line combination therapy for advanced NSCLC: a systematic review and network meta-analysis

Journal of the National Cancer Center · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles